Oculis Advances Dry Eye Precision Medicine with First Patient in PREDICT-1 Trial
Event summary
- Oculis randomized the first patient in the PREDICT-1 trial for Licaminlimab, a genotype-based treatment for dry eye disease (DED).
- The trial targets patients with a specific TNFR1 genotype, aiming to improve treatment efficacy in a market where only 13% of patients experience sustained relief.
- PREDICT-1 is a randomized, multi-center, double-masked, vehicle-controlled study planning to enroll ~160 patients.
- Licaminlimab has shown a five- to seven-fold more pronounced treatment effect in patients with a variant in the TNFR1 gene during Phase 2 trials.
The big picture
Oculis is pioneering a precision medicine approach in ophthalmology with Licaminlimab, targeting a specific TNFR1 genotype to address the significant unmet need in dry eye disease. The PREDICT-1 trial represents a strategic shift towards genotype-based treatments, potentially transforming the DED market where current therapies fail to provide sustained relief for the majority of patients. This approach aligns with broader industry trends towards personalized medicine and genetic biomarker-driven therapies.
What we're watching
- Clinical Efficacy
- Whether Licaminlimab can deliver sustained relief for a higher percentage of DED patients than current treatments.
- Regulatory Pathway
- The pace at which the FDA-aligned trial will progress and the likelihood of regulatory approval for Licaminlimab.
- Market Adoption
- How a precision medicine approach will be integrated into the current trial-and-error treatment paradigm for DED.